NASDAQ · HELP
Helus Pharma Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for HELP: Nov 12, 2026
Helus Pharma Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.67. The reported EPS for the same quarter last year was $-1.39.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.67 | $-0.67 | $-0.67 | 1 |
| Dec 2026 | $-0.68 | $-0.68 | $-0.68 | 1 |
| Mar 2027 | $-0.59 | $-0.59 | $-0.59 | 1 |
| Jun 2027 | $-0.59 | $-0.59 | $-0.59 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · MarketBeat · Zacks · RTTNews- Fintel · Oct 27, 2:18 PM EDTCybin Inc. Announces Co-Founders' Transition from Executive Leadership on October 27, 2026Helus Pharma Inc., formerly known as Cybin Inc., filed a Form 6-K on October 27, 2026, incorporating by reference its news release regarding executive leadership transitions.The company announced that co-founders Eric So and Paul Glavine have stepped down from their respective ex
- Fintel · Oct 22, 4:18 AM EDTHelus Pharma, Formerly Cybin Inc., Highlights Clinical Program Advancements at October 21, 2026 Investor PresentationHelus Pharma Inc., formerly Cybin Inc., provided highlights on the advancement of its lead clinical programs, HLP003 and HLP004, during an investor presentation held on October 21, 2026. The company reiterated that the topline data readout from its APPROACH Phase 3 study of HLP00
- MarketBeat · Oct 21, 2:04 PM EDTCybin Eyes Q4 Phase III Depression Data as Anxiety Program AdvancesMagic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast RaiseCybin (NASDAQ:HELP) outlined plans for two late-stage mental health programs, with top-line data from its Phase III APPROACH study of HLP003 in major depressive disorder expected later in the fourth quarter of 202
- Zacks · Oct 20, 11:00 AM EDTCybin Inc. (HELP) Upgraded to Buy: What Does It Mean for the Stock?Cybin Inc. (HELP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- MarketBeat · Sep 24, 6:02 AM EDTHelus Pharma Eyes Q4 Phase III Data for HLP-003 in Major DepressionMagic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast RaiseHelus Pharma, formerly known as Cybin (NASDAQ:HELP), outlined its late-stage development plans for HLP-003 in adjunctive major depressive disorder (MDD) and discussed its broader pipeline of serotonergic agonists
- MarketBeat · Sep 22, 9:02 AM EDTCybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member BoardMagic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast RaiseCybin (NASDAQ:HELP), doing business as Helus Pharma, held its Annual General and Special Meeting of Shareholders, where shareholders were asked to consider resolutions related to the company’s auditor, board size,
- MarketBeat · Sep 21, 1:02 AM EDTCybin Eyes Q4 Phase 3 Data for Depression Drug HLP003Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast RaiseCybin (NASDAQ:HELP) executives outlined plans for its late-stage depression program, including an expected fourth-quarter Phase 3 data readout for HLP003, during H.C. Wainwright’s 28th Annual Global Investment Con
- MarketBeat · Sep 20, 8:01 PM EDTCybin Eyes Q4 Phase III Depression Readout as Psychedelic Pipeline AdvancesMagic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast RaiseHelus Pharma Chief Executive Officer Michael Halstead said the company expects a pivotal Phase III readout for its HLP003 program in adjunctive major depressive disorder in the fourth quarter, describing the data
- MarketBeat · Aug 14, 7:04 AM EDTCybin Conference: Helus CEO Eyes Q4 Phase III Depression Data for HLP003Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast RaiseHelus Pharma CEO Michael Halstead said the company is preparing for a potentially pivotal period as it expects top-line results in the fourth quarter from its first Phase III trial of HLP003 as an adjunctive treat
- RTTNews · Aug 3, 8:46 AM EDTHelus Pharma Appoints Michael Halstead CEO, Effective Immediately(RTTNews) – On Monday, Cybin D/B/A Helus Pharma (HELP) announced that it has appointed Michael Halstead as Chief Executive Officer, effective immediately.
- RTTNews · Jun 25, 10:34 PM EDTTop Biotech Gainers: TECH Bought Out, MSLE On Watch, KYMR Hits New High, What's The Buzz At SLS?(RTTNews) – Today's top gainers in the biotech space include Bio-Techne, following acquisition news; Satellos Bioscience, gearing up to present new DMD data next month; and Kymera, which has revised its clinical data readout timeline, among others.
- RTTNews · Jun 24, 7:12 AM EDTHelus Pharma Surpasses 86% Enrollment In Phase 3 APPROACH Trial, Launches US $50 Million Offering(RTTNews) – Helus Pharma (HELP) reported strong clinical and financial momentum as the company announced that its Phase 3 APPROACH trial has surpassed 86% enrolment, while also pricing a US$50 million underwritten offering to support advancement of its mental-health pipeline.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Helus Pharma Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.